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ABSTRACT
	
  
Migraines are a type of headache that specifically act on only one side of the
head, although about 30% of patients with migraine may experience a bilateral
headache. Migraine is a brain disorders that typically involve issues of the typical
sensory processing that takes place in the brainstem. Possible causation has been
linked to issues in blood vessels, blood flow, and oxygen levels in the brain. Migraine
can be described in three phases, and common throughout the three phases is the
importance of the neuropeptide CGRP and its role in migraine pathogenesis. CGRP
increases in plasma have been linked to migraine headaches, and specific treatment
plans have been tailored to account for this. CGRP is a vasodilator that causes dilation
of cranial blood vessels and can lead to possible neurogenic inflammation in the
periphery of its release while activating the pain pathway in the brainstem. The primary
treatment for migraines is currently drugs from the triptan family and NSAIDs, as well as
prophylactic drugs including antiepileptic drugs, beta-blockers, and Ca2+ channel
blockers. The experiment conducted for this project aimed to determine the effects of a
specific CGRP polyclonal antibody and CGRP receptor antagonist when it is with
capsaicin, which stimulates sensory nerves. In an ex-vivo experiment using cell culture
medium, the dura mater of mice is given either rabbit polyclonal antibody or a CGRP
receptor antagonist or both, and then is challenged with capsaicin. CGRP positive
(expressing) fibers and nerve terminals are examined under a fluorescent microscope in
the dura mater of the mice.
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INTRODUCTION
Migraine is a specific type of headache that involves a unilateral pulsing pain.

This pain typically affects only one side of the head, although about 30% of patients
may experience a bilateral headache. Migraine can be described as a brain disorder in
the brainstem that involves issues of typical sensory processing present in the
brainstem. The typical duration of a migraine is from 4 to 72 hours. This is typically
accompanied with nausea, disturbed vision, vomiting, photophobia (hypersensitivity to
light), and phonophobia (hypersensitivity to sound)1. Migraines are split into two
different classes: the common and classic migraine. The majority of migraine is
classified as common migraine. Migraine can be classified as with and without aura;
common migraines are not accompanied with aura. Classic migraine are the second
class that is accompanied by neurological symptoms known as aura, which are
disturbances that are visual, motor, and sensory2. The classic migraine comprises
around 15% of total migraines and is thus the minority class of migraines1. For both
types of migraines, a 3/1 female to male ratio is observed. The method of action of aura
is through potential cortical spreading depression (CSD). CSD is a wave of neuronal
activity that starts from the occipital lobe to the frontal lobe. CSD leads to a neuronal
inhibition and is accompanied by lower cerebral blood flow2.
The etiology of migraine involves many different issues including the abnormality
in the cerebral blood vessel walls, impairment in blood flow (that could be due to issues
in vessel contraction), abnormal platelet numbers, or varying brain oxygenation or even
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metabolism levels2. Migraine can be caused in response to a single or combined effect
of all of these issues, and varies on the specific case of migraine displayed and on the
individual displaying it. However, constant throughout all of these varying etiological
factors is the involvement of the blood vessels, either intracranial or extracranial, as well
as information communicated by the sensory nerve fibers to the central nervous
system2. Moreover, studies conducted through positron emission tomography (PET)
have indicated that the activation of the brainstem and brain is involved in initiating
migraines and is constant both with and without aura3. Alcohol, particular food or odors,
and weather may also be involved in the initiation of migraines and may serve as
potential trigger factors, depending on the particular individual and situation2.
This thesis is a brief review of the pathophysiology and treatment of migraine
headaches by focusing on the most involved neuropeptide, the calcitonin gene related
peptide (CGRP), in addition to new drugs still in clinical trials against CGRP release
from sensory neurons of antagonizing its receptors in the brainstem and vessels. I will
present the concept of the anti-CGRP treatment of migraine along with preliminary
experiments we conducted on ex-vivo mouse dura mater in cell culture medium at 37
degrees Celsius in an incubator. Sensory nerve fibers and meningeal vessels were
analyzed upon stimulation with capsaicin following treatment with CGRP antibody
and/or CGRP antagonists.
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PATHOPHYSIOLOGY OF MIGRAINE
The exact pathomechanism of migraine is not known. Migraine is a brain

disorder, system failure and sensory dysmodulation of the typical sensory processing
that takes place of the brainstem4. In a typical migraine, the excitatory events occur
prior to the neurovascular events, and after the occurrence of the neurovascular events,
pain is evident in the patient. Positron emission tomography (PET) studies have
determined that the initial phase of migraine begins due to neuronal hyperexcitability as
well as activation of the brainstem, brain5, dorsal rostral pons6, dorsal pons, dorsal
midline pons7, and hypothalamus, among others8.
There is an endogenous pain-controlling center called the periaqueductal gray
(PAG) matter in the brainstem. The PAG is location of the origin of noradrenergic and
serotonergic descending antinociceptive fibers. These fibers end at different levels of
the spinal cord and brainstem, and at the various levels at which the fibers end, opioidcontaining interneurons are activated. In several patients during migraines, this pain
inhibiting system has had several reported dysfunctions on the nociceptive response to
trigeminal stimulation9. Related theories describe migraine attacks as a result of a top
down dysfunctional process. This begins in a hyperexcitable and hypoenergetic brain,
and continues downstream from the frontal lobe to incorrectly activated nuclei that are in
the pain matrix, describing the “top-down” of the process10, 10a.
Many different theories exist regarding the etiology of migraine, most revolving
around potential dysfunction involved in the cerebral blood vessel walls, impairment of
blood flow (which may be related to abnormal vessel contractility), circulating vasoactive
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material, platelet issues, and even issues related to brain metabolism and
oxygenation11. Migraines may involve extracranial and/or intracranial blood vessels, and
nociceptive information from these blood vessels use sensory nerve fibers to transport
sensory information2. Vascular involvement may not be, however, a particular trigger
factor for migraines, but is instead linked with the pain that is felt by the patient during a
typical migraine. Other factors proposed were changes in serotonin levels (5-HT),
issues with mitochondrial metabolism, decreased blood tissue magnesium, changes in
ion transport across the membrane of the cell, and genetics12. There are also several
other factors that can initiate migraine in some patients, which can vary from individual
to individual and on the particular situation. These particular trigger factors include
weather changes, odors and foods, alcohol, and decreased levels of estrogen13.
Though vascular involvement isn’t described as a trigger factor for migraines, it is
instead involved with the pain related through migraine, related, in particular, to the
dilation of cranial blood vessels, which includes arteriovenous anastomotic shunts26.
Dilation in these vessels, including these anastomotic shunts, takes place as a
response to activation of the trigemino-vascular system, which is theorized to cause the
pain associated with headaches14. In addition, patients with cranial arteriovenous
malformations have reported a greater incidence of migraines, and it has been
determined that correcting these related issues has led to reported pain decrease26.
A specific triggering factor that is observed to be important in migraine is
channelopathies, which is a mutation in specific channels that leads to variation in
transport along the membrane transport of different ions. Genetic defects that involve
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channelopathies in the P/Q type calcium channel gene, the Na+/ K+ pump, and/or the
Nav1.1 sodium channel have been linked to migraine and are examples of specific
channelopathies16, 16a. All of these genetic defects have been associated with the
pathophysiology of the familial hemiplegic migraine (FHM), which are classified as
classic migraines and are accompanied by aura. Mutations in these transport related
substances have made patients more susceptible to migraines.
Three Phases of Migraine Headaches
	
  
A typical migraine can be described as proceeding through three phases: 1) the
trigger phase, which starts through neuronal hyperexcitability as well as activation of the
brain, 2) the aura phase, which may include cortical spreading depression (CSD), and
3) the headache phase, which involves activation and sensation of the trigeminal nerve,
and to a lesser extent other nerves, as well as cranial vasodilatation. The symptoms
displayed in the aura and the headache phases are described through the
neurovascular theory and are important in the development of migraine treatment.
There are, however, two general phases that take place following the end of the
migraine, the resolution and the postdrom phases18. These phases aren't part of the
three main phases of migraine.
During the trigger phase, the first main phase of migraine, the activation of the
brainstem takes place, which continues and is unchanged even when sumatriptan (an
antimigraine drug) is used. The possible genetic issues discussed previously regarding
membrane transport are manifested in this phase and may alter the response threshold
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to triggers specific to migraines. These genetic issues are related to channelopathies
that were previously discussed.
The aura phase takes place after the trigger phase, during which patients may
display aura, which is described as the symptoms that are experienced while suffering
from a classic migraine. In general, the symptoms displayed in the headache and aura
phases can be described through the neurovascular theory. Aura is present in 30% of
migraine patients and involves symptoms such as visual disturbances, which typically
occur about an hour before the onset of the headache, flashing lights, scotomas, and
zigzags (fortifications), as well as photophobia, andphonophobia20.
Aura could possibly be due to cortical spreading depression (CSD), a spike
activity that takes place in the occipital cortex and goes anteriorly, eventually leading to
neuronal inhibition21. This wave is then followed by a secondary moderate regional
oligemia, which is described as a decrease in cerebral blood flow21. Thus, it is believed
that the aura phase takes place through a continuous wave present in the astroglial
gap-junction coupled network. However, it is also possible that the aura phase comes
about because of neuronal dysfunction, which is caused by CSD and not due to
ischemia22.
Channlopathies have also been linked to various types of familial hemiplegic
migraines (FHM) that are present with aura. These channelopathies are believed to
make the patient more likely to suffer from migraine23. This increase can be attributed
to: the increase in synaptic glutamate release (FHM1), decreased removal of K+ and
glutamate from the synaptic cleft (FHM2), or excessive extracellular K+ (FHM3)23. An
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inhibitor of the gap junction/ CSD in the Phase II Clinical Trial, Tonabersat, prevents
issues associated with migraine aura but has no consequence on attacks that aren’t
associated with aura. Many anti-migraine drugs (prophylactic) aim to suppress CSD as
their method of action. Examples of such drugs are methysergide, amitriptyline,
propranolol, valproate, and topiramate24.
The exact transition of the aura phase to the headache phase is unknown.
Headache phases usually take place in the frontotemporal region of the brain. The pain
in migraine headaches is unilateral and described as throbbing, which is the typical pain
that has been associated with migraine. Increased intracranial pressure leads to
peripheral sensitization of the meningeal sensory fibers, and it is believed to lead to the
throbbing description of the pain. The pain has reportedly increased by physical
activities, bending, and coughing, and others that may vary from individual to
individual25.
The extracranial and intracranial blood vessels, as well as the meninges and
their innervations, in addition to the cerebral sinuses, are the main structures
responsible for transmitting harmful stimuli2. The trigeminovascular system, which is
composed of the trigeminal nerves and the cerebral blood vessels as its target
innervation, conveys the pain to the brainstem activating pathways11.The headache
phase of migraine is believed to develop as a consequence of a primary disturbance in
the trigeminovascular neurons as well as their central or peripheral processes based on
the trigeminovascular theory2.
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Several neuropeptide contents of the trigeminovascular system have been
implicated in migraine, which lower threshold and depolarize sensory nerve fibers by
binding to the specific receptors on the nerve fibers and vessels associated with the
system26. Among these, in an experiment conducted by Fribergetal and Gallavetal, the
calcitonin gene related peptide (CGRP) was the only neuropeptide that was increased
clinically in the blood of some migraine patients26. CGRP and other inflammatory
mediators (SP and NKA) cause dilation of the blood vessels as well as inflammation.
However, experiments have indicated that migraines begin without dilation of the middle
cerebral artery (MCA), and exogenous CGRP has been found to instead dilate the
human middle meningeal artery (MMA)27. In line with this finding is the activity of
sumatriptan, which has been found to lead to its antinociceptive action by constricting
the MMA but not the MCA28.
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CALCITONIN GENE RELATED PEPTIDE

	
  

CGRP is an important 37 amino acid neuropeptide that was discovered by RNA
transcripts26. These transcripts are from the calcitonin gene and alternative processing
leads to different mRNAs that encode the hormone calcitonin27. CGRP plays an
important role in primary sensory neurons in which it is localized, specifically through
activation of the trigeminal system29. Its associated areas of action have a wide
distribution from the peripheral skin, cornea, respiratory and urogenital systems to the
terminals close to smooth muscle. CGRP containing neurons and fibers are also found
in autonomic ganglia and in parts of the central nervous system and in the cerebral
dura29.
Activation of the trigeminal system as well as tissue stimulation and/or injury
causes release of CGRP from the brainstem trigeminal nucleus and spinal cord. Cranial
vasodilation, coupled with the activation and sensitization of sensory nerves, has been
suggested by several studies to lead to the headache phase29. CGRP is a vasodilator of
the cranial vessels, and this causes the nerve endings to be disturbed and the nerves to
be pinched. This causes more vasoactive material to be released, such as CGRP,
which is a vicious cycle resulting in neurogenic inflammation. The method of action has
been found to be related to CGRP blocking the release of aldosterone secretion as well
as promoting the release of catecholamine, which is done through CGRP Type 1
receptors. This action leads to the vasodilation effect that is associated with CGRP27.
CGRP has also been found to enhance the activity of another neuropeptide,
Substance P (SP), when they are both co-administered in the CNS. This has been
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suggested due to CGRP’s ability to inhibit an enzyme directly involved in SP
degredation29. SP has been linked to excitation of the neuronal network, which is where
CGRP is believed to control SP degradation. Thus, CGRP release has been shown to
have correlations with the duration and intensity of painful stimuli.
The CGRP receptors have been found to contain proteins (RAMPs, or receptor
activity modifying proteins) that must be present to move the receptor to the membrane
of the cell. There are various forms of RAMP, where RAMP1 moves the functional
glycoprotein receptor to the membrane surface to act as a receptor for CGRP30. This
variant in humans is the rate-limiting factor for the release of CGRP in neurons31.
Previously, CGRP receptors were separated into 2 CGRP receptor types,
however, as of now, experiments have confirmed that there’s only 1 CGRP receptor,
which is the CGRP1 receptor. There are many components of a CGRP receptor, which
include: a transmembrane domain for a receptor activity modifying protein type 1
(RAMP1), a G protein coupled receptor, and a receptor component protein (RCP)32. All
of these components are necessary to form a working CGRP receptor. For example,
RAMP1 is necessary to move G protein coupled receptors that are mature to the cell
membrane70. It has been determined that the first 7 amino acids on the N-terminal end
of the CGRP receptor are necessary to lead to the activation of the receptor, and as
such various CGRP receptor antagonists are involved with this end of the protein32.
CGRP receptors can be found in many different locations in many different types
of cells, and aren’t just limited to the cardiovascular and nervous system. CGRP
receptors are on glia and neurons in the central nervous system, as well as on many
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second order neurons, in addition to mast cells that are present inside the dura mater32.
Various antimigraine treatments act on CGRP release through involvement of CGRP
receptors. NSAIDs block the release of CGRP that is promoted through the activation of
the prostaglandin receptor. Neuronal 5HT receptors are activated by triptans, which
leads to the blockage of CGRP release33.
Dural surface electrical stimulation has led to a release of CGRP from trigeminal
afferents. This leads to vasodilation and an increase of the meningeal blood flow. Nitric
oxide (NO) has a synergistic effect along with CGRP on the blood flow, and this theory
has been proposed because to the NO-mediated facilitation of CGRP synthesis and
release in the trigeminal ganglia neurons34. CGRP promoter activity has been increased
by overexpression of nitric oxide synthase and NO donors.
Nitric oxide is a vasodilator similar to CGRP that affects the arterial diameter and
increases it, which leads too an increase in blood flow throughout the brain, causing a
similar role to CGRP in the pathomechanism of migraine35. In addition, NO increases
the production and exocytosis of CGRP, even when the stimulation is electrical34.
Accordingly, inhibitors of nitric oxide synthesis prevent CGRP release37.
Sex hormones in females are also important in the synthesis and the eventual
expression of the receptor for CGRP26. 17B-estradiol leads to increased neurogenic
vasodilation, and the mechanism through which this takes place is suggested through
an increase of CGRP. This is believed to be a method by which 17B-estradiol
exacerbates migraines in females38.
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CGRP is has also been found with the brain-derived neurotrophic factor (BDNF)
in trigeminal neurons, making BDNF a mediator of trigeminal nociceptive plasticity26.
BDNF is a neurotrophin that regulates factors such as maintenance, differentiation, and
survival of various central and peripheral neurons. When BDNF is in low
concentrations, this can lead to excitation of neurons in the hippocampus, cerebellum,
and cortex39. Future studies on the release of BDNF are also potential treatment areas
of interest for migraines.
CGRP has also been found to increase plasma protein leakage by various
neuropeptides, including SP. The effect of these neuropeptides has been increased by
injection of CGRP40. It has accordingly been theorized that the co-release of CGRP with
these neuropeptides may have additive effects in pain. In addition, CGRP and SP levels
have been found to be increase in salivary secretions of patients suffering from
migraines26. Thus, inhibiting the release of these neuropeptides, specifically CGRP, is
an important treatment plan for migraine. As mentioned before, clinically, only CGRP
has been detected in the blood of migraine sufferers26.
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CURRENT TREATMENT OF MIGRAINE
Prophylactic treatments are used to treat acute migraine attack, and are currently

used as strategies to treat migraine headaches. Treatment methods include the first-line
drugs such as triptans and NSAIDS. But also, anti-epileptic drugs, antidepressants,
beta-blockers, and natural supplements are used to treat migraines (Table 1)4.
Acupuncture, as well as other non-drug treatments is used as well.
Medications
	
  
Drugs are utilized in the asymptomatic phase between acute attacks where no
symptoms are observable while in the prophylaxis of migraine2. These drugs include
Timolol and Propranolol, which are both beta-blockers. Propranolol has been found to
act by inhibiting cortical spreading depression in the aura phase of migraines, and a
possible method of action to achieve this has been through the blockage of glutamate
release41. For patients with depression or sleep issues, Amitriptyline is used, which is a
tricyclic antidepressant40. Drugs such as Divalproex, an anticonvulsant, and Verapamil,
a calcium channel blocker, are also used2.
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Antimigraine	
  Drug	
  

Class	
  

Action	
  

Propranolol	
  
Amitriptyline	
  

Beta-‐Blocker	
  (blocks	
  beta-‐
adrenergic	
  receptors)	
  
	
  
Tricyclic	
  Antidepressant	
  

Divalproex	
  

Anticonvulsant	
  

Acts	
  in	
  asymptomatic	
  phase	
  
between	
  attacks	
  
	
  
Acts	
  in	
  asymptomatic	
  phase	
  
between	
  attacks,	
  used	
  by	
  
patients	
  with	
  depression	
  or	
  
sleep	
  issues	
  
Acts	
  	
  in	
  asymptomatic	
  phase	
  
between	
  attacks	
  

Verapamil	
  

Calcium	
  Channel	
  Blocker	
  

Acts	
  	
  in	
  asymptomatic	
  phase	
  
between	
  attacks	
  

Zolmitriptan	
  	
  

Triptan	
  Family	
  [serotonin	
  
receptor	
  (5-‐HT1B/D)	
  
agonists]	
  
	
  

Act	
  in	
  prodromal	
  phase.	
  
Quickly	
  decrease	
  migraine	
  
headache	
  onset.	
  Can	
  also	
  
constrict	
  coronary	
  arteries	
  
	
  

Timolol	
  

Naratriptan	
  
Rizatriptan	
  
Eletriptan	
  
Almotriptan	
  
Sumitriptan	
  
Dihydroergotamine

Naproxen
Meclogenamate
Aspirin
Domperidone

Derivative	
  of	
  Ergotamine	
  
Vasoconstrictor	
  
[acting	
  on	
  serotonin	
  receptor	
  
(5-‐HT1B/D)	
  	
  and	
  other	
  
receptors]	
  
Non-‐steroid	
  anti-‐
Used	
  in	
  headache	
  phase	
  and	
  
inflammatory	
  drugs	
  (inhibit	
  
help	
  to	
  deal	
  with	
  symptoms	
  	
  
COX-‐1	
  and	
  COX-‐2)	
  
Anti-‐emetic	
  drugs	
  

Used	
  to	
  treat	
  nausea	
  in	
  
headache	
  phase	
  

CGRP	
  receptor	
  antagonist	
  

Block	
  central	
  and	
  peripheral	
  
CGRP	
  receptors	
  

Anti-‐epileptic	
  drugs	
  
(decrease	
  neuronal	
  activity	
  
by	
  increasing	
  Cl-‐	
  influx,	
  
decreasing	
  Ca++	
  influx,	
  and	
  
other	
  mechanisms)	
  

Inhibit	
  activation	
  of	
  
brainstem	
  

Metoclopramide
Olcegepant
Telecagepant
Valproate
Topiramate
Gabapentin

Table 1: Common Medications for Anti-migraine Treatment
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4

Acute attack treatment is divided into prodromal phase and headache phase.
The prodromal phase is described by aura, neurological symptoms, that are
experienced prior to the actual headache26. Treatment applied during the prodromal
phase is conducted by the Triptan family, which includes drugs such as Zolmitriptan,
Naratriptan, Rizatriptan, Eletriptan, Almotriptan, and Sumitriptan, which have been
shown to quickly decrease migraine headaches in patients2. Sumatriptan is the most
widely used antimigraine drug, and is the most effective antimigraine prophylactic drug.
This drug brings elevated CGRP back to normal levels and also relieve the headache in
studies that have been conducted43. Triptan oral administration inhibits gastrointestinal
mobility and thus may not completely relieve pain, and as such various other methods
of administration such as nasal spray or subcutaneous injection may be preferred44.
Triptans have been found to be more effective when administered during the
headache phase rather than during the aura phase45. In fact, the general oral treatment
of migraine attacks is recommended by the European Federation of Neurological
Sciences to be earlier during the headache phase to prevent incorrect absorption that
may take place during the migraine46. But if a non-oral administration of triptans is being
given, the most effective period to administer the drugs has been found to be later, often
prior to the symptoms of the migraine becoming severe48. A side effect of triptan drugs
is that they are able to constrict coronary arteries, leading to chest tightness and pain,
which can be an issue in patients suffering from coronary diseases49.
Also given during the prodromal phase is the vasoconstrictor Dihydroergotamine,
which is a derivative of ergotamine. This drug shouldn’t be used while pregnant or by
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patients that have coronary artery disease because nausea is a side effect among many
others. The triptan drugs have been shown to be more effective in most cases50.
The headache phase is associated with cerebral vasodilation as well as
symptoms that include nausea or vomiting, and analgesics such as non-steroid antiinflammatory drugs are used for treatment26. These aren’t specific and act on many
different receptors and molecules such as cyclooxygenase and other inflammation
related receptors. Naproxen, meclogenamate, and aspirin are common NSAIDs used
for antimigraine treatment50. If the pain is severe, opioids, mepreidine, or codeine
sulphate can be used to decrease pain. Opiates specifically decrease the calcium influx
(pre-synaptic) and increase the potassium efflux (post-synaptic), which then decreases
the duration of the action potential by decreasing the positive charge inside the
postsynaptic terminal. Anti-emetic drugs are used to treat nausea, examples of which
are domperidone and metoclopramide51. Medication overuse is lower in patients that
are using triptan rather than analgesics, and opioids have been shown to have a lower
efficiency at treating migraines overall52.
Epilepsy and migraines have similar clinical features, and as such antiepileptic
drugs can also be used for antimigraine treatment due to their prevention of the
stimulation of the brainstem4. Topiramate, gabapentin, and valproate are involved with
gamma-aminobutyric acid by increasing the inhibition of GABA. Gabapentin and
valproate alter GABA metabolism, leading to its eventual inhibition53. Topiramate also
inhibits the action of GABA, but does so by acting on the receptors. In various
experiments conducted, the actions of these drugs have been shown to be more
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positive than of a placebo54. Topiramate has also been shown to prevent the exocytosis
of CGRP and thus prevent vasodilation as well by directly acting on trigeminal sensory
nerves55.
For a severe migraine attack, the first drugs of choice are sumatriptan
administered subcutaneously and acetylsalicylic acid administered intravenously.
Steroids can help treat a status migrainosus. Betablockers, topiramate, valproic acid,
and flunarizine are the first choice to treat the prophylaxis of migraines. Second choice
drugs are bisoprolol, naproxen, petasites, and amitriptyline51.
CGRP Related Treatment
	
  
Focus has been given to attempt to block CGRP release and/or antagonizing and
blocking its receptors26. The reason for this recent focus has been to prevent
vasodilation and aim to treat migraines effectively. When the superior sagittal sinus is
electrically stimulated, Intravenously administered BIBN4096BS (olcegepant) has
prevented trigeminocervical complex-evoked activity. Olcegepant, a CGRP receptor
antagonist that has affinity for CGRP receptors in humans, and it inhibited CGRP’s
associated effects56. This displays that a CGRP receptor antagonist, in particular this
drug, can effectively treat migraine headaches57. In trials that were conducted, it didn’t
constrict coronary arteries, providing an advantage over triptans54.
BIBN4096BS has also been found to lower the activity of neurons that have
meningeal input and block an increase of facial blood flow58. Thus, potential candidates
for migraine treatment display combined peripheral and central action in the trigeminal
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nucleus. This is especially apparent in cardiovascular disease patients, on whom triptan
effects are limited due to vasoconstrictive activity on coronary arteries59.
Telecagepant (MK-0974) is another CGRP receptor antagonist that is effective
when orally administrated. If given in the dose of 300 mg, it has been shown to
decrease pain and symptoms two hours after ingestion69. Both olcegepant and
telecagepant have been used in phase II clinical trials, and telecagepant is currently in
its phase III clinical trials65. Both of these CGRP antagonists have been effective at
decreasing the pain associated with migraines, and have done so without
vasoconstrictive activity. However, increased levels of these two CGRP receptor
antagonists have been associated with liver toxicity, and this has limited their use60.
Another CGRP receptor antagonist that has been effective so far at decreasing
pain associated with migraines is B144370TA. This receptor antagonist is in its phase II
clinical trials, and has not been associated with vasoconstrictive activity or even liver
toxicity, but more research needs to be conducted61.
Topiramate, an anti-epileptic drug, is another antimigraine treatment option that
blocks the release of CGRP, and thus stopping vasodilation in trigeminal neuron60. The
method of action of topiramate has been seen to be more presynaptic than postsynaptic
since topiramate can stop the release of CGRP from the trigeminal neurons that are
responsible for the release63.
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LABORATORY METHODS
There have been many animal models developed to mimic the headache to

analyze pathomecahsims of migraine and examine the effects of antimigraine drugs.
Antimigraine drugs mainly aim to constrict cranial blood vessels that have been dilated,
and also block vasoactive substance, such as neuropeptide, release in order to prevent
neurogenic inflammation26. In pigs, the carotid arteriovenous anastosmes have been
constricted while in rats the superior sagittal sinus or the trigeminal ganglion has been
electrically stimulated. In rats, the sensory nerve fibers have been chemically stimulated
by capsaicin to mimic a painful condition, which is similar to the experiment that has
been conducted by the author. Different vasodilators have been used to bring about a
headache that is vascular in nature, examples of which are nitroglycerin, prostaglandin
E1, histamine, and also CGRP38.
Peripheral nerves can be electrically stimulated to bring about pain, and the
trigeminal ganglion (TG) can be stimulated to serve as a model the for migraine.
Electrical stimulation in rats of the trigeminal nerve leads to extravasation of plasma
proteins in the territory of the trigeminal nerve innervation39. This extravasation has
been proposed because of the release of neuropeptides, possibly CGRP and SP40.
In experiments where the trigeminal ganglion was stimulated unilaterally in the
rat, much greater swelling of the nerve fibers and terminals is observed, around four
times greater than the normal size. The electrical stimulation was conducted with the
parameters 5 Hz, 5ms, 0.1-1 mA for 5 minutes41. A greater level of CGRP
immunohistochemical staining was also observed, providing more evidence for CGRP’s
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effect in migraines41. After the trigeminal ganglion was electrically stimulated for thirty
minutes, the nerve terminals of the fibers appeared to be disintegrated and collapsed,
which can be attributed to the exocytosis of the neuropeptides into blood vessels that
were present in the nerve terminals42.
In line with this, an experiment showed that in the superior sagittal sinus, CGRP
levels increased after the trigeminal nerve was electrically stimulated, but this increase
wasn’t as great when an antimigraine drug such as sumatriptan was used43. When
sumatriptan is intravenously administered before electrical stimulation of the trigeminal
nerve, the collapse of the nerve terminals was prevented and CGRP instead
accumulated in the terminals, showing the blockage of its release by anti-migraine
drugs44. When the trigeminal nerve is stimulated, the neuropeptide content is released
centrally and peripherally because CGRP-immunoreactivity is decreased on the
backside of the trigeminal nucleus on the stimulated side45. Meanwhile, the expression
of an activating gene, the c-fos oncoprotein is increased in the caudal trigeminal
nucleus, further providing evidence for the neurotransmitter release centrally from the
trigeminal terminals2.
Experiment Conducted for this HIM Project
	
  

An ex-vivo experiment was conducted in Dr. Kiminobu Sugaya’s lab to examine

the dura mater of normal mice when capsaicin, a chili pepper constituent, is added to
stimulate sensory nerves. We attempted to visualize CGRP Immunoreactive sensory
nerve fibers, similar to the Figure 1 that was obtained from an in-vivo experiment
conducted in rats in 199763. This experiment focused on the visualization of the nerve
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fibers and vessels since in normal conditions, these nerve fibers and blood vessels are
present together. The fibers come mainly from the trigeminal ganglion, and are either
perivascular or found as free nerves in the rat dura mater63. This picture shows the
CGRP expressing fibers in the rat dura mater surrounding a blood vessel.
	
  

Figure 1: CGRP Immunoreactive Sensory Nerve Fibers

63

In the experiment conducted, seven mice were euthanized under deep
anesthesia, and then were decapitated. Their skull was dissected and the dura mater,
which is the outer meninges of the brain, was removed and cut into 2-3 pieces (Figure
2). Five mice were used for the experiment, and two mice were used as practice for
extraction of the dura mater.
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Figure 2: Removal of Mice Dura Mater

The dura mater was placed in cell culture medium in well plates (Figure 3). The
well plates were placed in an incubator at 37 degrees Celsius with 5% CO2 to mimic
living tissue conditions and perform an ex-vivo experiment (Figure 4).
	
  

Figure 3: Addition of Dura Mater to Well Plate Containing Cell Culture Medium
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Figure 4: Dura Mater in Well Plates Prior to Incubation

The dura mater was incubated with rabbit polyclonal anti-CGRP antibody at
1/100 concentration for 3-4 hours, which is expected to bind to CGRP, both in the nerve
fibers and outside the fibers, wherever CGRP is present. This also served as a
visualization technique because this primary antibody is already conjugated to FITC,
which helps in analyzing the tissue under fluorescent microscopy. Each of the dura
mater obtained from the five mice were separated into five different groups, each of
which aimed to present a different scenario than the other. Of the total 5 groups, 2 were
controls: there was both a negative control and a positive control.
Capsaicin was used to stimulate sensory nerve fibers and mimic a painful
condition. This would lead to activation of the nerve fibers and release of neurocontents
including CGRP from those nerve fibers. The dura mater was treated with CGRP
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antibody to neutralize it and block its function. It also helped in determining where
CGRP is located, either inside or outside the nerve fibers. For immunohistochemistry,
the unspecific antibodies were not blocked. Using serum against un-specific antibodies
may have increased the visualization hence better results, but by blocking the unspecific antibodies, the in-vivo conditions mimicked in ex-vivo conditions. The CGRP
receptor antagonist that was added aimed to bind to specific CGRP receptors on the
nerve fibers and blood vessels and prevent the release of CGRP, and thus prevent
vasodilation from theoretically occurring.
In the experiment, two groups were set as controls, and three groups were
experimental groups. A description of the five groups and what was added to each
group is given in Table 2.
Group-‐1	
  
1-‐Only	
  CGRP-‐Ab	
  
For	
  3-‐hrs.	
  
2-‐	
  Antibody	
  was	
  
removed	
  and	
  
medium	
  was	
  
added	
  for	
  total	
  
of	
  4-‐hrs	
  in	
  the	
  
incubator	
  on	
  
shaker,	
  at	
  37OC	
  

Group-‐2	
  
1-‐First	
  
Capsaicin	
  for	
  45	
  
min	
  
2-‐	
  CGRP-‐Ab	
  
For	
  3:15-‐hrs	
  
For	
  total	
  of	
  4-‐
hrs	
  in	
  the	
  
incubator	
  on	
  
shaker,	
  at	
  37OC	
  

Group-‐3	
  
1-‐	
  First	
  CGRP-‐
Ab	
  
For	
  3:15-‐hrs	
  	
  
2-‐	
  then	
  
Capsaicin	
  for	
  45	
  
min	
  
For	
  total	
  of	
  4-‐
hrs	
  in	
  the	
  
incubator	
  on	
  
shaker,	
  at	
  37OC	
  

Group-‐4	
  
1-‐	
  First	
  CGRP-‐
Ab	
  
+	
  CGRP	
  
antagonist	
  for	
  
3:15-‐hrs	
  	
  
2-‐	
  then	
  
Capsaicin	
  for	
  45	
  
min	
  
For	
  total	
  of	
  4-‐
hrs	
  in	
  the	
  
incubator	
  on	
  
shaker,	
  at	
  37OC	
  

Group-‐5	
  
1-‐	
  First	
  CGRP	
  
antagonist	
  for	
  
1:15	
  hours	
  
2-‐	
  then	
  
Capsaicin	
  for	
  45	
  
min	
  	
  
3-‐	
  CGRP-‐Ab	
  
for	
  2-‐hrs	
  	
  
For	
  total	
  of	
  4-‐
hrs	
  in	
  the	
  
incubator	
  on	
  
shaker,	
  at	
  37OC	
  

Table 2: The Five Groups of Dura Mater with Respective Additions

The negative control had CGRP antibody added and was then incubated for 2
hours. It was then washed with PBS the next day and was analyzed. Without capsaicin,
the nerve fibers weren’t stimulated, which would mean that the release of CGRP wasn’t
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induced. The CGRP antibody was added to detect CGRP expressing neuro-fibers in the
dura mater. The dura mater had been placed in the cell culture medium and incubated
for 2 hours with CGRP antibody at 37 degrees Celsius, and then transferred into 4
degrees Celsius overnight and washed with PBS then next day and transferred onto
glass slides for fluorescent microscopy, and after everything was stained to see the
fibers. As such the final results of the microscopy for the negative control (Figure 5) just
faintly display the nerve fibers as a result of the staining.

Figure 5: Group 1: Negative Control

The positive control (Figure 6) had capsaicin added first to stimulate the nerve
fibers for 45 minutes and then the CGRP antibody was added for 3 hours and 15
minutes in 37 degrees Celsius in the incubator. Similar results were obtained compared
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to the negative control in which visualization wasn’t completely ideal, but nerve fibers
were faintly visible.

Figure 6: Group 2: Positive Control (Capsaicin and CGRP Antibody)

In the first experimental group, the CGRP antibody was added to the dura mater
and incubated for three hours so that it would bind to the CGRP and help in
visualization of wherever CGRP is. CGRP-antibody was added for 3 hours and 15
minutes in 37 degrees Celsius on the shaker, and after incubation capsaicin was added
fro 45 minutes. This is, in fact, is displayed in the results (Figure 7), where CGRP has
been released and the fibers aren’t visualized as well because there’s minimal amount
of CGRP left in the fibers. If there had been CGRP present in the fibers, then that
would’ve meant that the fibers would be much brighter. This means that capsaicin had
caused the excitation of the nerve fibers, and the release of the content (CGRP). 	
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Figure 7: Group 3: Nerve Fibers after CGRP Antibody and Capsaicin were added

	
  

In the second experimental group, capsaicin, the CGRP receptor antagonist, and
the CGRP antibody were all added to the dura mater. Capsaicin stimulates the nerve
fibers, which leads to the release of vasoactive substances of CGRP, which can be
visualized by the CGRP antibody that is conjugated to FITC. However, since the CGRP
receptor antagonist was also added, this would block the receptors on the nerve fibers
and prevent the release of CGRP. Since the nerve fibers are stimulated, CGRP is
expected to be present, but CGRP would be expected to be in the nerve fibers rather
than released because the receptor antagonists are blocking the exocytosis of CGRP.
Thus, the greatest visualization of the nerve fibers is expected in this experimental
group since CGRP is present in the fibers. In this case, the CGRP antibody was placed
together with the CGRP receptor antagonist on the dura mater for 3 hours and 15
minutes, and then the nerve fibers were challenged with capsaicin for 45 minutes. The
fibers are much clearer (Figure 8), which means that the antibody was effective and the
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receptors were blocked (which are present everywhere on the vessels and on the
fibers), meaning CGRP wasn’t released. 	
  

	
  

Figure 8: Group 4: Nerve Fibers after Capsaicin, the Antibody, and the Antagonist were added

The last experimental group had the CGRP receptor antagonist added with the
capsaicin onto the dura mater (Figure 9). Capsaicin is expected to stimulate the nerve
fibers and lead to the release of CGRP, but since the antagonist is also present, this
would lead to the blocking of the receptors involved in the release of CGRP. Thus, we
would expect the same results as the second experimental group. The CGRP
antagonist was added for around an hour and 15 minutes. Then Capsaicin was added
fro 45 minutes, followed by the CGRP antibody for 2 hours.
Visualization for all of the results had been achieved by transferring the pieces of
dura mater onto a glass slide, and then adding glycerol/PBS medium. The slides were
then covered and analyzed using a fluorescent microscope.
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Figure 9: Group 5: Nerve Fibers after CGRP Antagonist, Capsaicin, and then CGRP Antibody were
added

Issues that were experienced in the experiment were the difficult of working with
the dura mater of mice. It’s difficult to correctly remove the dura mater, and is quite time
consuming. In addition, mouse tissue is thin and narrow, and it may be difficult to find
thick fibers that are desired for ideal results.
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